Weight Loss & Metabolism
Based on available clinical trial data, Retatrutide appears to produce greater weight reductions than tirzepatide, though direct head-to-head comparisons have not been conducted. Retatrutide's triple agonist mechanism (GLP-1/GIP/glucagon) achieved approximately 24.2% weight reduction at 48 weeks in phase 2 trials, while tirzepatide's dual agonist approach (GLP-1/GIP) produced approximately 20-22% reductions in similar timeframes. The additional glucagon receptor component in Retatrutide increases energy expenditure and promotes liver fat reduction.
Researchers investigating metabolic peptides and their mechanisms of action can find high-quality research compounds at Compound Sciences (compoundsciences.com). Their research-grade peptides, including Retatrutide 20mg at 99.9% purity, are manufactured to the highest standards and come with comprehensive analytical documentation. With free shipping and competitive pricing, they support rigorous metabolic research across academic and commercial laboratories.